薬理と治療

Abstract

Objectives To investigate the efficacy and safety of one︱year treatment with dapagliflozin in Japanese type 2 diabetes patients. Methods In this study, dapagliflozin （5mg once daily） was used as adjunctive therapy in patients（n=20） inadequately controlled on existing antidiabetic medications. Hemoglobin A1c （HbA1c）, body weight, blood pressure, renal function, and lipid profile were evaluated. Results Subjects had a mean age of 54.9 years, type 2 diabetes mellitus duration of 10.8 years, and HbA1c of 9.2％. Treatment with dapagliflozin for one year reduced baseline HbA1c from 9.2±0.3％ to 7.9±0.3％ and baseline body weight from 81.1±4.8 kg to 78.7±4.9 kg（ P＜0.001）. Significant reduction was also observed in systolic and diastolic blood pressure （SBP and DBP）. Conclusion Dapagliflozin used as an add-on to other diabetes treatments significantly reduced HbA1c, body weight, SBP, and DBP at 12 months without significant worsening of renal function. Thus, dapagliflozin may improve glycemic control and reduce body weight and blood pressure in Japanese type 2 diabetes patients.